DelveInsight’s “Alzheimer’s Disease Pipeline Insight” report provides comprehensive insights about key companies and pipeline drugs in the Alzheimer’s Disease pipeline landscapes.
The report comprises Alzheimer’s Disease pipeline drug profiles, including clinical and non-clinical stage products. It also includes the Alzheimer’s Disease therapeutics assessment by product type, stage, route of administration, and molecule type and further highlights the inactive Alzheimer’s Disease pipeline products.
Alzheimer’s Disease Overview
Alzheimer’s disease is a debilitating neurological disorder that gradually erodes memory and cognitive abilities, as well as the ability to perform even the most basic tasks. Alzheimer’s patients have difficulty doing simple tasks such as driving a car, preparing a meal, or paying bills. They can repeatedly ask the same questions, become easily disoriented, accidentally drop or misplace objects, and find even simple things perplexing. Some people become worried, frustrated, or aggressive as the disease progresses.
•Alzheimer’s disease is a disease whose precise causes are unknown. However, at a fundamental stage, brain proteins malfunction, disrupting the work of brain cells (neurons) and triggering a cascade of toxic events. Neurons become weakened, lose their ties, and ultimately die.
Some of the key takeaways from the Alzheimer’s Disease Pipeline Report:
-
Companies across the globe are diligently working toward the development of novel treatment therapies with a considerable amount of success over the years. Key players, such as Eisai/ BioArctic AB, Biogen, Hoffmann-La Roche, Cortexyme, Otsuka Pharmaceutical, etc., are developing therapies for the treatment of Alzheimer’s Disease.
-
Emerging therapies such as Lecanemab (BAN2401), Aducanumab (BIIB037), Gantenerumab, Atuzaginstat (COR388), Brexpiprazole, are expected to have a significant impact on the Alzheimer’s Disease market in the coming years.
Get an overview of pipeline landscape @ Alzheimer’s Disease Clinical Trials Analysis
Alzheimer’s Disease Pipeline Therapies along with Key Players:
-
Lecanemab (BAN2401): Eisai/BioArctic AB
-
Aducanumab (BIIB037): Biogen
-
Gantenerumab: Hoffmann-La Roche
-
Atuzaginstat (COR388): Cortexyme
-
Brexpiprazole: Otsuka Pharmaceutical
Scope of Alzheimer’s Disease Pipeline Drug Insight
-
Coverage: Global
-
Major Players: Eisai/ BioArctic AB, Biogen, Hoffmann-La Roche, Cortexyme, Otsuka Pharmaceutical, and others.
-
Pipeline Therapies: Lecanemab (BAN2401), Aducanumab (BIIB037), Gantenerumab, Atuzaginstat (COR388), Brexpiprazole, and others.
Table of Contents
|
1 |
Alzheimer’s Disease Report Introduction |
|
2 |
Alzheimer’s Disease Executive Summary |
|
3 |
Alzheimer’s Disease Overview |
|
4 |
Alzheimer’s Disease- Analytical Perspective In-depth Commercial Assessment |
|
5 |
Alzheimer’s Disease Pipeline Therapeutics |
|
6 |
Alzheimer’s Disease Late Stage Products (Phase II/III) |
|
7 |
Alzheimer’s Disease Mid Stage Products (Phase II) |
|
8 |
Alzheimer’s Disease Early Stage Products (Phase I) |
|
9 |
Alzheimer’s Disease Preclinical Stage Products |
|
10 |
Alzheimer’s Disease Therapeutics Assessment |
|
11 |
Alzheimer’s Disease Inactive Products |
|
12 |
Company-University Collaborations (Licensing/Partnering) Analysis |
|
13 |
Alzheimer’s Disease Key Companies |
|
14 |
Alzheimer’s Disease Key Products |
|
15 |
Alzheimer’s Disease Unmet Needs |
|
16 |
Alzheimer’s Disease Market Drivers and Barriers |
|
17 |
Alzheimer’s Disease Future Perspectives and Conclusion |
|
18 |
Alzheimer’s Disease Analyst Views |
|
19 |
Appendix |
|
20 |
About DelveInsight |
Get a customized pipeline report @ Alzheimer’s Disease Drugs Pipeline Report.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/